Danaher has entered into a definitive agreement to acquire Integrated DNA Technologies (IDT), a privately held provider of consumables for genomics applications. IDT primarily manufactures custom DNA and RNA oligonucleotides serving more than 100,000 global customers in the academic and biopharmaceutical research, biotechnology, agriculture, clinical diagnostics, and pharmaceutical development end markets. The company also manufactures products used in diagnostic tests for many forms of cancer and most inherited and infectious diseases. Danaher’s acquisition of IDT is expected to be complete by midyear 2018, after which IDT will function as a standalone operating company and brand within Danaher’s Life Sciences platform. “IDT expands our presence into the highly attractive genomics market and will help play a central role in accelerating our customers’ research and time to market as they develop critical diagnostic tests and potential life-saving therapies,” said Rainer Blair, executive vice president of Danaher’s Life Sciences platform.